CLINICAL TRIALS
Travere Therapeutics is committed to research and development of new therapies for rare diseases.
We are involved in numerous clinical trials for our pipeline product candidates.
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)
Investigational therapy: Sparsentan
Therapeutic area: FSGS, IgAN, minimal change disease, IgA-associated vasculitis, Alport syndrome
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986
RESTORE Study
Investigational therapy: Chenodeoxycholic acid
Therapeutic area: CTX
Study type: Phase 3
Learn more: CTXrestore.com | NCT04270682
REPLACE Registry
Investigational therapy: Cholic acid
Therapeutic area: BASD; PBD-ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086
COMPOSE Study
Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611
Natural History Study of Homocystinuria Caused by Cystathionine Beta-synthase Deficiency
Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT03406611
HONUS Study: Humanistic Burden of FSGS and IGAN
Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871
DUPLEX Study
Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: fsgsduplex.com | NCT03493685
DUET Study
Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118
PROTECT Study
Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: iganprotect.com | NCT03762850
CTX Prevalence Study
Therapeutic area: CTX among patients with early-onset idiopathic bilateral cataracts
Study type: Observational
Learn more: NCT02638220
MA-304